Edwards Lifesciences Corp EW

Zacks Investment Research 13 nov

Zacks analysts published research on 16 major stocks on November 13, 2026. Visa benefits from strong brand and digital growth but faces profitability pressures. ExxonMobil gains from low-cost production and expansion opportunities but faces commodity volatility risks. Pfizer underperforms peers due to patent expirations and subdued growth, though pipeline investments offer longer-term potential. Additional coverage includes U.S. Bancorp, Blackstone, Edwards Lifesciences, and others with mixed outlooks.

Zacks Investment Research 12 nov

Boston Scientific's WATCHMAN left atrial appendage closure device continues to face declining demand despite positive clinical trial results and expansion efforts. The company expects low-single-digit sequential sales declines in Q3 2026 and assumes no market improvement in 2027, while competitors like Abbott and Edwards Lifesciences show stronger momentum in electrophysiology and structural heart segments.

GlobeNewswire Inc. 12 nov

The global Transcatheter Aortic Valve Replacement (TAVR) market is projected to grow from US$ 8.41 billion in 2025 to US$ 30.01 billion by 2035, driven by increasing prevalence of aortic stenosis, aging populations, and rising adoption of minimally invasive cardiac procedures. Technological advancements in valve platforms and delivery systems are creating growth opportunities, with Asia Pacific emerging as the fastest-growing region.

Zacks Investment Research 5 nov

Intuitive Surgical reported a 28% year-over-year increase in da Vinci system placements to 546 units in Q3 2026, with systems revenues rising 30% to $769M. The growth was driven by multisystem orders, hospital capacity expansions, and upgrades to the da Vinci 5 platform. Recurring revenues represented 84% of Q3 sales, reflecting strong system utilization. However, the article notes that capital spending remains uneven and sustained acceleration will depend on continued healthy capital spending and higher procedure volumes.

Zacks Investment Research 2 nov

Solventum (SOLV) is set to report Q3 2026 earnings on Nov. 5 with projected 8% earnings decline and 6% revenue decline. While MedSurg and Dental segments show strong momentum and Acera demonstrates 48% Q2 growth, the company faces headwinds from a $125M ERP-related order reversal, tariff pressures, and margin compression. Despite challenges, Zacks' model predicts an earnings beat with a +10.15% Earnings ESP and Rank #3 rating.